<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882517</url>
  </required_header>
  <id_info>
    <org_study_id>PCL_2010_024</org_study_id>
    <nct_id>NCT01882517</nct_id>
  </id_info>
  <brief_title>Lipid-lowering Effect of Plant Stanol Yogurt</brief_title>
  <official_title>The Cholesterol Lowering Efficacy of Plant Stanol Ester Yoghurt in a Turkish Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raisio Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Raisio Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of investigational products on serum LDL cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy of plant stanols as esters on LDL-cholesterol reduction is well documented.&#xD;
      LDL-cholesterol lowering efficacy of the ingredient administered in a yogurt is less well&#xD;
      known.&#xD;
&#xD;
      Study was monitored by Foodfiles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum LDL cholesterol</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipidemias</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Yogurt that contains plant stanol esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Yogurt that contains plant stanol esters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo yogurt</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Placebo yogurt</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Yogurt that contains plant stanol esters</intervention_name>
    <arm_group_label>Yogurt that contains plant stanol esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo yogurt</intervention_name>
    <arm_group_label>Placebo yogurt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects must voluntarily sign the informed consent&#xD;
&#xD;
          -  subjects must be male or female aged 20 to 70 years&#xD;
&#xD;
          -  subjects must have a serum total cholesterol concentration of 5.2 - 7.5 mmol/l ( 205 -&#xD;
             290 mg/dl) at the screening visit (visit 1, -2 week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subjects using lipid lowering medication&#xD;
&#xD;
          -  subjects using ezetimibe&#xD;
&#xD;
          -  subjects with bile acid sequestrant medication&#xD;
&#xD;
          -  subjects with statin therapy&#xD;
&#xD;
          -  subjects using other medication significantly influencing on lipid values&#xD;
&#xD;
          -  subjects with diagnosis type 1 or type 2 diabetes&#xD;
&#xD;
          -  severe obesity (BMI&gt;35.0 kg/m2)&#xD;
&#xD;
          -  serum fasting triglycerides &gt; 4.0 mmol/l&#xD;
&#xD;
          -  subjects with any hepatic or renal disorder according to medical history&#xD;
&#xD;
          -  subjects who have history of myocardial infarction or unstable angina pectoris within&#xD;
             six months prior to screening&#xD;
&#xD;
          -  subjects who have history of coronary artery bypass graft or percutaneous transluminal&#xD;
             coronary angioplasty within six months prior to screening&#xD;
&#xD;
          -  subjects who have history of temporal ischemic attack or stroke within six months&#xD;
             prior to screening&#xD;
&#xD;
          -  subjects who have a history of cancer or other malignant disease within the past five&#xD;
             years&#xD;
&#xD;
          -  subjects with abnormal values of health screening variables measured at screening&#xD;
             visit: serum gamma-glutamyltransferase&gt; 2 x upper limit, serum alkaline phosphatase&gt; 2&#xD;
             x upper limit or other abnormality in laboratory evaluations considered as clinically&#xD;
             significant in the opinion of the study physician&#xD;
&#xD;
          -  subjects who are consuming more than 15 portions of alcohol / week&#xD;
&#xD;
          -  subjects who are pregnant or lactating&#xD;
&#xD;
          -  subjects using Benecol, Becelpro.activ, Danacol or other plant sterol enriched&#xD;
             products within 30 days before visit 2&#xD;
&#xD;
          -  subjects with severe lactose intolerance, milk allergy or any other intolerance to the&#xD;
             ingredients of test products&#xD;
&#xD;
          -  celiac disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hacettepe University</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

